## Media Watch

## You can always pop a pill

Gavin Yamey, Deputy editor, wjm

Competing interests: None declared

West J Med 2001;174:382

On billboards and at bus stops in the Castro, San Francisco's gay district, advertisements for HIV drugs show beefy male models looking like the picture of perfect health. Similar ads in the local gay press show beautiful men climbing mountains or sailing boats. These direct-to-consumer ads are perfectly legal in the United States, so is there anything wrong with these upbeat images?

The city's daily newspapers certainly thought so. "Dubious message in bus shelters," read the headline in the *San Francisco Chronicle* (March 15, 2001). The paper reported that a band of AIDS activists, together with the Department of Public Health, believe that the ads send out "too positive a message" about living with HIV.

"San Francisco to consider banning some ads for AIDS drugs," said the San Jose *Mercury News* (March 15, 2001). Its story focused on the possibility that the city might become the first in the United States to outlaw these ads altogether.

Activists believe that the ads do not give an accurate picture of what it is like to live with HIV and to take HIV drugs, which can have serious and unpleasant side effects. In the ad that has caused the greatest outrage, one for Crixivan (indinavir), 4 attractive men in hiking gear are shown on top of a rocky mountaintop, gazing into space. The headline reads, "going the distance."

"That's a phony and distorted image of what it's like to have AIDS," said Jeff Getty of the activist organization Survive AIDS in an interview with the *Chronicle*. "On these drugs, you don't feel like climbing a mountain."

Jeffrey Klausner, an epidemiologist in the city's health department, agrees. "Usually the ads have large, sexy models and fine print of what the side effects are," he told the paper. "These medicines don't enable anyone with HIV to climb mountains. The side effects make it impossible."

What's more, claims Klausner, the ads may have played a part in the recent rise in the rate of HIV infection among gay men in San Francisco (*BMJ* 2001;322:260). The ads, he believes, may fuel the idea that HIV is easily treatable and that safe sex is therefore unnecessary.

To back up his beliefs, Klausner has taken the unusual step of releasing preliminary data (available at www.surviveaids.org) from his survey of men attending the city's sexual health clinics. The data are incomplete—only 262 men, out of a target of 1000, have so far been interviewed. Nevertheless, Klausner told the press that 62% of men surveyed believed that the ads "affect a person's decision to have unprotected sex." Gay men who saw the ads regularly, he said, were more likely to have unprotected sex than those who seldom noticed them.

"Because these preliminary data were so compelling," he told the *Chronicle*, "I thought it necessary to bring it to public attention."

Tom Ammiano, president of the city's Board of Supervisors, finds these preliminary data persuasive and called a public hearing on April 12th to discuss a ban on the ads. "These ads," he told me, "are saying subliminally that the condition is not so serious—you can always pop a pill—which plays into why some young men are practicing unsafe sex."

If the city bans the ads, which it has the legal power to do, will the US Food and Drug Administration follow suit and impose a national ban?

Unlikely, says Richard Klein, from the administration's Office of Special Health Issues. "I'm not a fan of direct-to-consumer advertising," he said, "but these ads are not in violation of the rules. The information about the side effects of the drugs is there in the ads, albeit buried in small type." For the administration to take a regulatory position, he said, it would need "much better data" to support



Are advertisements for HIV and AIDS drugs too positive?

a link between the ads and unsafe sex. If the city does ban the ads, he believes, it could well be faced with a lawsuit from the advertisers.

Klein agrees that the ads may not be representative of all gay men living with HIV, but he says there is no legal duty to represent all such patients in the images used. He agrees that it may be tasteless to show sexualized images of gay men in ads for HIV drugs, but the administration is "not the taste police," he says.

Merck & Co. says that its ad for indinavir provides a useful educational function. Kyra Lindemann, spokeswoman for the company, said: "The visual of the ad was intentional—to describe the ability of individuals to overcome HIV. The purpose of the ad is to stimulate patients to go and discuss treatment options with their physicians."

Back in the Castro, a gay man is about to have sex. He has seen the ads for HIV drugs, and perhaps these influence whether or not he puts on a condom. Such causality is of course difficult to prove. One thing that he did see in the ads was a mixed message: a sexy image being used to sell a drug for a sexually transmitted infection. And that, as Klausner says, "is like using Big Macs to sell drugs that lower your cholesterol."

382 wjm Volume 174 June 2001 www.ewjm.com